ATI vs LII

ATI has a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm solvency. Despite strong recent earnings growth (YoY EPS +41.7%) and solid ROE of 24.62%, the stock trades at a steep valuation (P/E 39.85, Price/Book 9.83) well above the Graham Number of $29.6, suggesting significant growth expectations are already priced in. Insider selling activity worth $20.38M over the past six months signals caution, while analysts maintain a strong_buy consensus with a $133.00 target. The combination of rich multiples, weak financial health signals, and negative insider sentiment offsets strong profitability and growth metrics, resulting in a neutral outlook.

LII exhibits significant financial deterioration, highlighted by a weak Piotroski F-Score of 3/9 and a massive valuation gap where the current price ($495.52) trades at a severe premium to both its Graham Number ($130.92) and Intrinsic Value ($159.53). While the company maintains high ROE and profitability, these are offset by negative YoY revenue (-11.20%) and earnings growth (-17.90%). The combination of bearish insider sentiment, a failing technical trend, and poor liquidity (Quick Ratio 0.52) suggests a high risk of price correction.